Baiji Shenzhou's product revenue increased by 81% year-on-year in the first three quarters of 2023, reaching 10.984 billion yuan
我放心你带套猛
发表于 2023-11-10 12:33:44
243
0
0
On November 10, 2023, Baekje Shenzhou (NASDAQ: BGNE; Hong Kong Stock Exchange: 06160.HK; Shanghai Stock Exchange: 688235. SH) announced its US stock performance report and A-share performance report for the third quarter of 2023.
According to the A-share performance report, Baiji Shenzhou achieved a total operating revenue of 5.624 billion yuan in the third quarter, a year-on-year increase of 111.5%. Thanks to strong demand for core products, product revenue maintained a high growth rate this quarter, reaching 4.287 billion yuan, a year-on-year increase of 79.2%.
In the first three quarters of 2023, the total operating revenue of Baekje Shenzhou was 12.875 billion yuan, an increase of 87.4% year-on-year. In the first three quarters, the product revenue of Baekje Shenzhou exceeded the 10 billion mark for the first time, reaching 10.984 billion yuan, a year-on-year increase of 81%, significantly exceeding the full year product revenue of last year.
Zebutinib has significant global sales, with overseas revenue exceeding 80%
As the first innovative drug approved by Baekje Shenzhou in the international market, this year, Baekje&Co; Reg; Global sales have achieved continuous month on month growth, with overseas revenue accounting for over 80% in the third quarter. Zebutinib's global sales in the third quarter reached 2.571 billion yuan, a year-on-year increase of approximately 130%. Among them, the sales revenue in the United States reached 1.937 billion yuan, an increase of more than double compared to 740 million yuan in the same period last year. In China, Zebutinib's sales reached 344 million yuan, compared to 270 million yuan in the same period last year.
Currently, Zebutinib has been approved in over 65 markets and has established a wide range of clinical development layouts worldwide. In addition, Baekje Shenzhou has submitted a new indication marketing license application for the treatment of follicular lymphoma (FL) with Zebutenib combined with Otuzumab to the US FDA and has been accepted. The FDA is expected to make a decision on this application in March 2024. Zebutinib has received positive feedback from the European Medicines Agency (EMA) Committee on Human Medicines (CHMP) regarding this marketing approval application.
Zebutinib's continuous success in the international market not only reflects the differentiated competitiveness of Baekje's self-developed products, but also proves the correctness and strong execution ability of its independent global commercial layout. At present, Baekje Shenzhou has a commercialization team of over 500 people overseas, with main personnel recruited locally, covering mainstream markets such as North America and Europe, truly achieving global "localization".
PD-1 goes to sea with "zero breakthrough", accelerating global layout to benefit patients
In addition, another core self-developed product of Baekje Shenzhou, PD-1 Antibody Baekzean& Reg; Tirelizumab was first approved in the European Union for second-line treatment of adult patients with esophageal squamous cell carcinoma (ESCC), achieving a "zero breakthrough" in the PD-1 field.
At the same time, Baekje is accelerating the global registration plan for tirelizumab. In the United States, the FDA is reviewing the application for a new drug marketing license to treat second-line ESCC with tirelizumab, and is expected to approve the application within 2023 or the first half of 2024. In addition, EMA is reviewing the marketing license application for the combination of tirelizumab and chemotherapy for first-line and second-line treatment of metastatic non-small cell lung cancer (NSCLC), and it is expected that EMA will approve this application in the first half of 2024. In 2024, Baekje will also submit marketing approval applications in the United States, the European Union, Japan, and China, further expanding the global layout of tirizumab.
In China, the market share of tirizumab continues to increase, with sales reaching 1.046 billion yuan in the third quarter, compared to 879 million yuan in the same period last year. So far, over 750000 patients have received treatment with tirelizumab. At present, 11 indications of tirelizumab have been approved by the China National Drug Administration, of which 9 indications have been included in the national medical insurance drug catalog.
The financial report shows that Baekje Shenzhou has entered the next wave of research and development, and is fully advancing towards "first in class" or "best in class". At present, Baekje Shenzhou has a rich global R&D pipeline reserve, with a total of 23 development projects and over 60 preclinical projects under research. (Yan Yun)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Joyful Group: Q2 2024 revenue growth of 3.3% year-on-year
- Southern Financial Research News | Tianfeng Securities' Guo Mingchi: Nvidia's revenue expectation for the third quarter of fiscal year 2025 is lower than the buyer's expectation
- Q2 revenue increased by 98.9% year-on-year, while the US stock market rose more than 4% before trading! NIO claims that its bankrupt has been arrested by the police for spreading rumors
- TSMC's net revenue for August was approximately NT $250.87 billion, a year-on-year increase of 33.0%
- TSMC's August sales revenue reached NT $250.87 billion, a year-on-year increase of 33%
- TSMC's August sales revenue reached NT $250.87 billion, a year-on-year increase of 33%
- Goldman Sachs CEO takes precautions: third quarter performance may not be ideal, trading business tends to decline by 10%
- Dozens of AI tools, big promotion of learning and training JD strives to increase the number of small and micro businesses with daily sales exceeding 10000 yuan by more than twice year-on-year on November 11th
- Mid Autumn Festival welcomes online shopping peak, with Dingdong buying groceries and mooncake sales expected to increase by over 30% year-on-year
- NIO: Approximately 21200 vehicles delivered in September, a year-on-year increase of 35.4%
-
9月が終わり、映画・テレビ業界が暗躍している。最近、愛奇芸の創始者でCEOのGONG宇氏は、映画・テレビ業界が長短の変化、AIの変化、中国映画・テレビドラマの海外進出の変化の3つの変化を経験していると発表した。 ...
- 寒郁轩良
- 昨天 14:17
- 支持
- 反对
- 回复
- 收藏
-
ネットワーク状況監視サイトDownDetectorによると、オーディオストリーミングプラットフォームSpotifyは日曜日に約3時間にわたる障害を経験した後、正常に回復し、ピーク時には米国の4万人以上のユーザーに影響を与 ...
- hecgdge4
- 昨天 09:33
- 支持
- 反对
- 回复
- 收藏
-
百済神州(688235.SH)はA株の有名な革新薬企業で、2017-2024年上半期、同社の各期の研究開発投資はA株の化学製薬会社(申万二級)の中で最も高く、研究開発費用は合計600億元を超えた。 しかし、百済神州にとって ...
- wylz8473
- 前天 18:36
- 支持
- 反对
- 回复
- 收藏
-
10月1日、極クリプトン自動車が発表したデータによると、今年第3四半期に新車が累計14万2900台納入され、前年同期比81%増となった。このうち、9月に新車を納入したのは2万13万人で、前年同期比77%、前月比18%増だっ ...
- 内托体头
- 5 小时前
- 支持
- 反对
- 回复
- 收藏